journal
Journals Alimentary Pharmacology & Ther...

Alimentary Pharmacology & Therapeutics

https://read.qxmd.com/read/38429885/inflammatory-bowel-disease-ibd-patients-with-impaired-quality-of-life-on-biologic-therapy-benefit-from-the-support-of-an-ibd-nurse-specialist-results-of-a-randomised-controlled-trial-in-germany-ibd-bio-assist-study
#21
JOURNAL ARTICLE
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
BACKGROUND: IBDBIO-ASSIST was a randomised controlled trial assessing the efficacy of care provided by IBD nurse specialists in Germany in improving health-related quality of life (QoL) in IBD patients on biologic therapy. AIM: To evaluate patient-related outcomes and economic consequences associated with integrating IBD nurses into usual care. METHODS: We randomly assigned 1086 patients with IBD on biologic therapy to a control group (CG) receiving usual care or an intervention group (IG) receiving additional care from an IBD nurse specialist...
March 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38425096/camp-b-score-predicts-the-risk-of-hepatocellular-carcinoma-in-patients-with-chronic-hepatitis-b-after-hbsag-seroclearance
#22
JOURNAL ARTICLE
Hye Won Lee, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Young-Suk Lim, Henry Lik-Yuen Chan, Sang Hoon Ahn, Grace Lai-Hung Wong, Jonggi Choi
BACKGROUND: Risk of hepatocellular carcinoma (HCC) persists after hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB). AIMS: To identify risk factors and construct a predictive model for HCC development. METHODS: We retrospectively analysed patients with CHB with HBsAg seroclearance. Primary outcome was HCC development. Factors identified from a multivariate Cox model in the training cohort, consisting of 3476 patients from two Korean hospitals, were used to construct the prediction model...
February 29, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38425022/impact-of-inflammatory-bowel-disease-on-the-risk-of-acute-coronary-syndrome-a-swedish-nationwide-cohort-study
#23
JOURNAL ARTICLE
Carl Eriksson, Jiangwei Sun, Matti Bryder, Gabriella Bröms, Åsa H Everhov, Anders Forss, Tomas Jernberg, Jonas F Ludvigsson, Ola Olén
BACKGROUND: There are conflicting data on the risk of acute coronary syndrome (ACS) in patients with inflammatory bowel disease (IBD). Only a few previous reports include patients diagnosed during the last decade. AIM: To assess and compare the risk of ACS between patients with IBD and the general population. METHODS: In this cohort study, we used nationwide registers to identify patients diagnosed with IBD in Sweden 2003-2021. Every patient was matched by birth year, sex, calendar year and area of residence with up to 10 general population comparators...
February 29, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38414095/terlipressin-therapy-is-associated-with-increased-risk-of-colonisation-with-multidrug-resistant-bacteria-in-patients-with-decompensated-cirrhosis
#24
JOURNAL ARTICLE
Marcus M Mücke, María Hernández-Tejero, Wenyi Gu, Michael Kuhn, Malte Janz, Marisa I Keller, Anthony Fullam, Laura Altepeter, Victoria T Mücke, Fabian Finkelmeier, Katharina M Schwarzkopf, Carla Cremonese, Peter-Merton Hunyady, Myriam W Heilani, Frank Erhard Uschner, Robert Schierwagen, Maximilian J Brol, Julia Fischer, Sabine Klein, Kai-Henrik Peiffer, Michael Hogardt, Saeed Shoaie, Minneke J Coenraad, Jörg Bojunga, Vicente Arroyo, Stefan Zeuzem, Volkhard A J Kempf, Christoph Welsch, Wim Laleman, Peer Bork, Javier Fernandez, Jonel Trebicka
BACKGROUND: Patients with cirrhosis are susceptible to develop bacterial infections that trigger acute decompensation (AD) and acute-on-chronic liver failure (ACLF). Infections with multidrug-resistant organisms (MDRO) are associated with deleterious outcome. MDRO colonisation frequently proceeds MDRO infections and antibiotic therapy has been associated with MDRO colonisation. AIM: The aim of the study was to assess the influence of non-antibiotic medication contributing to MDRO colonisation...
February 27, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38410882/persistently-high-hbsag-levels-during-hbeag-seropositive-stage-predict-lower-risk-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-patients
#25
JOURNAL ARTICLE
Hsin-Che Lin, Wen-Juei Jeng, Jessica Liu, Mei-Hung Pan, Mei-Hsuan Lee, Richard Batrla-Utermann, Sheng-Nan Lu, Chuen-Fei Chen, Hwai-I Yang, Chien-Jen Chen
BACKGROUND: High hepatitis B surface antigen (HBsAg) level predicts hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with low viral load. The role of longitudinal HBsAg levels in predicting HCC in HBeAg-positive CHB patients remains unknown. METHOD: HBeAg-positive CHB participants from the REVEAL-HBV cohort with ≥2 HBsAg measurements before HBeAg seroclearance were enrolled. Group-based trajectory modelling identified distinct HBsAg trajectory groups during a median of 11 years of HBeAg-positive status...
February 27, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38409879/evaluation-of-potential-hepatic-recompensation-criteria-in-patients-with-pbc-and-decompensated-cirrhosis
#26
JOURNAL ARTICLE
Benedikt Silvester Hofer, Lukas Burghart, Emina Halilbasic, Benedikt Simbrunner, Oleksandr Petrenko, Mattias Mandorfer, Albert Friedrich Stättermayer, Michael Trauner, Thomas Reiberger
BACKGROUND: Aetiological therapy improves liver function and may enable hepatic recompensation in decompensated cirrhosis. AIMS: We explored the potential for recompensation in patients with decompensated primary biliary cholangitis (PBC) - considering a biochemical response to ursodeoxycholic acid (UDCA) according to Paris-II criteria as a surrogate for successful aetiological treatment. METHODS: Patients with PBC were retrospectively included at the time of first decompensation...
February 26, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38404263/branched-chain-amino-acid-supplementation-does-not-improve-measures-of-sarcopenia-in-cirrhosis-results-of-a-randomised-controlled-trial
#27
JOURNAL ARTICLE
Penelope Hey, Rudolf Hoermann, Marie Sinclair, Brooke Chapman, Adam Testro, Ross Apostolov, Peter Angus, Paul Gow
BACKGROUND: Sarcopenia is associated with adverse outcomes in cirrhosis. Branched-chain amino acids (BCAA) target several pathways that lead to muscle loss in this population. AIMS: We aimed to evaluate the impact of BCAA supplementation on sarcopenia measures in patients with cirrhosis. METHODS: We conducted a 12-month double-blinded, randomised, controlled trial of BCAA supplementation (30 g daily) compared to an equicaloric, equi-nitrogenous whey protein in volunteers with cirrhosis and reduced muscle strength...
February 26, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38389319/high-dose-proton-pump-inhibitor-treatment-is-associated-with-a-higher-mortality-in-cirrhotic-patients-a-multicentre-study
#28
JOURNAL ARTICLE
Jun Sik Yoon, Ji Hoon Hong, Soo Young Park, Seung Up Kim, Hwi Young Kim, Ju Yeon Kim, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Han Ah Lee, Gi-Ae Kim, Dong Hyun Sinn, Sung Jae Park, Youn Jae Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee
BACKGROUND: Proton pump inhibitors (PPI) are frequently used in patients with cirrhosis. AIMS: This study aimed to determine whether PPI use is associated with the prognosis of cirrhotic patients. METHODS: We conducted a multicentre retrospective cohort study involving 1485 patients who had experienced hepatic encephalopathy (HE) from 7 referral centres in Korea. The primary outcome was overall survival and secondary outcomes included the development of cirrhotic complications, including recurrent HE, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and gastrointestinal bleeding...
February 22, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38385884/uk-guideline-on-the-transition-and-management-of-childhood-liver-diseases-in-adulthood
#29
REVIEW
Deepak Joshi, Jeremy Nayagam, Lisa Clay, Jenny Yerlett, Lee Claridge, Jemma Day, James Ferguson, Paul Mckie, Roshni Vara, Henry Pargeter, Rachel Lockyer, Rebecca Jones, Michael Heneghan, Marianne Samyn
INTRODUCTION: Improved outcomes of liver disease in childhood and young adulthood have resulted in an increasing number of young adults (YA) entering adult liver services. The adult hepatologist therefore requires a working knowledge in diseases that arise almost exclusively in children and their complications in adulthood. AIMS: To provide adult hepatologists with succinct guidelines on aspects of transitional care in YA relevant to key disease aetiologies encountered in clinical practice...
February 22, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38372477/upper-limit-of-normal-alt-levels-in-health-and-metabolic-diseases-pooled-analysis-of-423-355-individuals-with-bootstrap-modelling
#30
JOURNAL ARTICLE
Eunice X Tan, Daniel Q Huang, Natasha Tang Sook Yee, Zi Hui Wan, Sanjna N Nerurkar, Justin Chua Ying Kai, Kang Shiong Goh, Cheng Han Ng, Mark Muthiah, Yu Zhou, Amanda Woodward, Michael H Le, Yee Hui Yeo, Scott Barnett, Ramsey Cheung, Mindie H Nguyen
INTRODUCTION: Given the global rise in obesity-related metabolic diseases, the upper limit of normal (ULN) alanine aminotransferase (ALT) in individuals with and without metabolic diseases may have changed. We performed a meta-analysis combined with bootstrap modelling to estimate the ALT ULN levels for individuals with and without metabolic diseases. METHODS AND RESULTS: Two separate searches of the PubMed, Embase and Cochrane databases were performed, one to identify healthy individuals which yielded 12 articles (349,367 individuals); another to include those with potential metabolic diseases but without known liver disease which yielded 35 articles (232,388 individuals)...
February 19, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38372406/meta-analysis-risk-of-pancreatic-cancer-in-patients-with-inflammatory-bowel-disease
#31
REVIEW
Mohammad Zamani, Shaghayegh Alizadeh-Tabari, Mohammad Hassan Murad, Ashwin N Ananthakrishnan, Reza Malekzadeh, Nicholas J Talley
BACKGROUND: Studies exploring the association between inflammatory bowel disease (IBD) and pancreatic cancer have reported inconsistent results. AIMS: To provide a comprehensive overview of the risk of pancreatic cancer development in patients with IBD. METHODS: We searched Embase, PubMed, Scopus and ProQuest from inception to 31 October 2023. We included population-based cohort studies examining the risk of incident pancreatic cancer in adult patients with IBD compared to the non-IBD population...
February 19, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38372012/drug-induced-liver-injury-from-selective-androgen-receptor-modulators-anabolic-androgenic-steroids-and-bodybuilding-supplements-in-australia
#32
JOURNAL ARTICLE
Emily Nash, Amanda Nicoll, Nicholas Batt, Jacob George, Varan Perananthan, David Prince, Michael Wallace, Paul Gow, Karl Vaz, Shivakumar Chitturi, Joan Ericka Flores, Alicia Braund, Mark Bonnichsen, Stephen Riordan, Jeremy Humphris, Tuan Duong, Catriona McKenzie, Ken Liu, Simone I Strasser
BACKGROUND: Reports of DILI due to herbal and dietary supplements have been increasing over time. AIMS: To characterise clinical, laboratory and histopathological phenotypes and outcomes of drug-induced liver injury (DILI) due to anabolic-androgenic steroids (AAS), selective androgen receptor modulators (SARMs), and bodybuilding supplements (BBS) in Australia. METHODS: Retrospective case series. Patients presented to nine Australian tertiary hospitals, 2017-2023...
February 19, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38327102/an-algorithm-based-on-immunotherapy-discontinuation-and-liver-biopsy-spares-corticosteroids-in-two-thirds-of-cases-of-severe-checkpoint-inhibitor-induced-liver-injury
#33
JOURNAL ARTICLE
Mar Riveiro-Barciela, Ana Barreira-Díaz, María-Teresa Salcedo, Ana Callejo-Pérez, Eva Muñoz-Couselo, Patricia Iranzo, Carolina Ortiz-Velez, Susana Cedrés, Nely Díaz-Mejía, Juan Carlos Ruiz-Cobo, Rafael Morales, Juan Aguilar-Company, Ester Zamora, Mafalda Oliveira, María-Teresa Sanz-Martínez, Lluis Viladomiu, Mónica Martínez-Gallo, Enriqueta Felip, María Buti
BACKGROUND: There are few data on corticosteroids (CS)-sparing strategies for checkpoint inhibitor (ICI)-induced liver injury (ChILI). AIM: We aimed to assess the performance of a 2-step algorithm for severe ChILI, based on ICI temporary discontinuation (step-1) and, if lack of biochemical improvement, CS based on the degree of necroinflammation at biopsy (step-2). METHODS: Prospective study that included all subjects with grade 3/4 ChILI...
February 7, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38321716/high-prevalence-of-mafld-in-general-population-a-large-cross-sectional-study-calls-for-concerted-public-health-action
#34
JOURNAL ARTICLE
Tushar Prabhakar, Manya Prasad, Guresh Kumar, Kanica Kaushal, Priyanka S Shenoy, Shantanu Dubey, Shiv Kumar Sarin
BACKGROUND: Metabolic associated fatty liver disease (MAFLD) is a relatively new term with limited studies done in South Asian population. AIM: To determine prevalence and clinico-epidemiological characteristics of MAFLD in general population. METHODS: A cross-sectional study was conducted in randomly selected regions across Delhi, India. Data were collected on socio-demographic particulars, health status and lifestyle factors. Anthropometric measurements, transient elastography, and laboratory investigations were carried out...
February 6, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38311841/worldwide-population-prevalence-and-impact-of-sub-diagnostic-gastrointestinal-symptoms
#35
JOURNAL ARTICLE
Olafur S Palsson, Jan Tack, Douglas A Drossman, Boris Le Nevé, Laurent Quinquis, Rim Hassouna, Johannah Ruddy, Carolyn B Morris, Ami D Sperber, Shrikant I Bangdiwala, Magnus Simrén
BACKGROUND: The Rome Foundation Global Epidemiology Study (RFGES) found that 40.3% of adults in 26 internet-surveyed countries met Rome IV criteria for disorders of gut-brain interaction (DGBI). However, additional people not meeting DGBI criteria may also be burdened by frequent gastrointestinal symptoms. AIMS: To explore the prevalence and demographic distribution of sub-diagnostic gastrointestinal symptoms, and the hypothesised associated effects on quality of life (QoL), life functioning and healthcare needs...
February 4, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38303565/prevalence-and-impact-of-alcohol-abstinence-in-alcohol-associated-cirrhosis-systematic-review-and-meta-analysis
#36
REVIEW
Wen Hui Lim, Phoebe Tay, Cheng Han Ng, Darren Jun Hao Tan, Christen Ong, Jia Hong Koh, Margaret Teng, Douglas Chee, Zhen Yu Wong, Takumi Kawaguchi, Hirokazu Takahashi, Mark Muthiah, Eunice X X Tan, Karn Wijarnpreecha, Guan Huei Lee, Mazen Noureddin, Brian P Lee, Philippe Mathurin, Rohit Loomba, Daniel Q Huang
BACKGROUND: Although alcohol abstinence may be an effective intervention for alcohol-associated cirrhosis, its association with prognosis has not been systematically assessed or quantified. AIMS: To determine the prevalence of alcohol abstinence, factors associated with alcohol abstinence and the impact of abstinence on morbidity and overall survival in people with alcohol-associated cirrhosis. METHODS: We searched Medline and Embase from inception to 15 April 2023 for prospective and retrospective cohort studies describing alcohol abstinence in people with known alcohol-associated cirrhosis...
February 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38303507/machine-learning-improves-the-prediction-of-significant-fibrosis-in-asian-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-the-gut-and-obesity-in-asia-go-asia-study
#37
JOURNAL ARTICLE
Nipun Verma, Ajay Duseja, Manu Mehta, Arka De, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ruveena Bhavani Rajaram, Wah-Kheong Chan, Sanjiv Mahadeva, Ming-Hua Zheng, Wen-Yue Liu, Sombat Treeprasertsuk, Thaninee Prasoppokakorn, Satoru Kakizaki, Yosuke Seki, Kazunori Kasama, Phunchai Charatcharoenwitthaya, Phalath Sathirawich, Anand Kulkarni, Hery Djagat Purnomo, Lubna Kamani, Yeong Yeh Lee, Mung Seong Wong, Eunice X X Tan, Dan Yock Young
BACKGROUND: The precise estimation of cases with significant fibrosis (SF) is an unmet goal in non-alcoholic fatty liver disease (NAFLD/MASLD). AIMS: We evaluated the performance of machine learning (ML) and non-patented scores for ruling out SF among NAFLD/MASLD patients. METHODS: Twenty-one ML models were trained (N = 1153), tested (N = 283), and validated (N = 220) on clinical and biochemical parameters of histologically-proven NAFLD/MASLD patients (N = 1656) collected across 14 centres in 8 Asian countries...
February 1, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38297816/meta-analysis-efficacy-and-safety-of-fibroblast-growth-factor-21-analogues-for-the-treatment-of-non-alcoholic-steatohepatitis-and-non-alcoholic-steatohepatitis-related-fibrosis
#38
REVIEW
Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng
BACKGROUND: Fibroblast growth factor 21 (FGF21) analogues have emerged as promising therapeutic targets for non-alcoholic steatohepatitis (NASH). However, the effects and safety of these analogues on NASH and NASH-related fibrosis remain unexplored. AIMS: To estimate the efficacy and safety of FGF21 analogues for treating NASH and NASH-related fibrosis. METHODS: PubMed, Embase, and the Cochrane Library were searched for relevant studies up to 11 October 2023...
January 31, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38240626/corrigendum
#39
(no author information available yet)
No abstract text is available yet for this article.
January 19, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38234285/higher-end-of-treatment-hbsag-levels-is-associated-with-later-onset-but-not-severe-relapse-in-hbeag-negative-chronic-hepatitis-b-patients-stopping-antivirals
#40
JOURNAL ARTICLE
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
BACKGROUND: Quantitative hepatitis B surface antigen (qHBsAg) level at end-of-treatment (EOT) predict clinical relapse (CR) after nucleos(t)ide analogues (Nuc) in chronic hepatitis B(CHB) patients. It is unclear if higher EOT qHBsAg leads to earlier onset or more severe off-Nuc CR. AIM: This large cohort study investigates the association between EOT qHBsAg and CR onset/severity. METHODS: This study enrolled HBeAg-negative CHB patients who had achieved undetectable HBV DNA for over 1 year after receiving Nuc therapy before discontinuation...
January 18, 2024: Alimentary Pharmacology & Therapeutics
journal
journal
29552
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.